S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
NASDAQ:FNCH

Finch Therapeutics Group Stock Forecast, Price & News

$8.56
+0.12 (+1.42%)
(As of 01/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.10
▼
$8.93
50-Day Range
$8.38
▼
$16.88
52-Week Range
$7.29
▼
$22.50
Volume
27,332 shs
Average Volume
37,764 shs
Market Capitalization
$406.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive FNCH News and Ratings via Email

Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter.


About Finch Therapeutics Group

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn's disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc.; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Headlines

Finch Therapeutics Group, Inc. Common Stock (FNCH)
January 20, 2022 |  nasdaq.com
Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Short Interest Up 58.1% in December
January 16, 2022 |  americanbankingnews.com
Finch Therapeutics Further Strengthens Patent Portfolio with Two New U.S. Patents Granted for FIN-211, an Investigational Microbiome Therapeutic in Development for Autism Spectrum Disorder
January 6, 2022 |  finance.yahoo.com
Finch Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference
January 4, 2022 |  finance.yahoo.com
Trade Alert: The Independent Director Of Finch Therapeutics Group, Inc. (NASDAQ:FNCH), Nicholas Haft, Has Just Spent US$650k Buying 1.6% More Shares
December 23, 2021 |  finance.yahoo.com
Finch Therapeutics Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
December 20, 2021 |  finance.yahoo.com
We're Keeping An Eye On Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Rate
December 17, 2021 |  finance.yahoo.com
Finch Therapeutics to Participate in Upcoming Investor Conferences
November 11, 2021 |  benzinga.com
Finch Therapeutics Announces Transition of Chief Medical Officer
November 10, 2021 |  finance.yahoo.com
Finch Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
November 10, 2021 |  finance.yahoo.com
Finch Therapeutics' C. Difficile Infection Candidate Meets Primary Goal In Mid-Stage Study
November 10, 2021 |  finance.yahoo.com
Finch Therapeutics Presents Positive Data from PRISM3 Clinical Trial of CP101 for Recurrent C. difficile at American College of Gastroenterology Annual Scientific Meeting
October 25, 2021 |  finance.yahoo.com
Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors
October 5, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FNCH
Previous Symbol
CUSIP
N/A
CIK
1733257
Web
www.finchtherapeutics.com
Phone
617-229-6499
Fax
N/A
Employees
131
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
17.64
Quick Ratio
17.64

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
47,479,000
Free Float
N/A
Market Cap
$406.42 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/25/2022
Next Earnings (Estimated)
2/09/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

1.75 out of 5 stars

Medical Sector

901st out of 1,416 stocks

Biological Products, Except Diagnostic Industry

136th out of 206 stocks

Analyst Opinion: 3.5Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Finch Therapeutics Group (NASDAQ:FNCH) Frequently Asked Questions

Is Finch Therapeutics Group a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Finch Therapeutics Group in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Finch Therapeutics Group stock.
View analyst ratings for Finch Therapeutics Group or view top-rated stocks.

Are investors shorting Finch Therapeutics Group?

Finch Therapeutics Group saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 253,900 shares, an increase of 58.1% from the December 15th total of 160,600 shares. Based on an average daily volume of 111,000 shares, the short-interest ratio is currently 2.3 days. Approximately 1.5% of the shares of the company are short sold.
View Finch Therapeutics Group's Short Interest.

When is Finch Therapeutics Group's next earnings date?

Finch Therapeutics Group is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Finch Therapeutics Group.

How were Finch Therapeutics Group's earnings last quarter?

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.21. The company earned $11.34 million during the quarter.
View Finch Therapeutics Group's earnings history.

What price target have analysts set for FNCH?

3 brokers have issued twelve-month target prices for Finch Therapeutics Group's shares. Their forecasts range from $25.00 to $34.00. On average, they anticipate Finch Therapeutics Group's stock price to reach $29.33 in the next year. This suggests a possible upside of 242.7% from the stock's current price.
View analysts' price targets for Finch Therapeutics Group or view top-rated stocks among Wall Street analysts.

Who are Finch Therapeutics Group's key executives?

Finch Therapeutics Group's management team includes the following people:
  • Dr. Mark Burnham Smith, CEO & Director (Age 34, Pay $644.52k)
  • Dr. Zain Kassam FRCPC, M.D., M.P.H., Co-Founder & Chief Medical Officer (Age 39, Pay $618.53k)
  • Mr. Gregory D. Perry, Chief Financial Officer (Age 61, Pay $581.31k)
  • Ms. Kristine Callahan CPA, Sr. Director of Accounting
  • Mr. Andrew Noh, Chief Admin. Officer
  • Mr. Joseph D. Vittiglio J.D., Esq., Gen. Counsel & Corp. Sec. (Age 49)
  • Mr. James S. Sigler, Exec. VP of CMC (Age 60)
  • Ms. Sonia Timberlake, Sr. VP of Research
  • Dr. Michelle L. Rose, Chief Regulatory Officer

When did Finch Therapeutics Group IPO?

(FNCH) raised $101 million in an initial public offering on Friday, March 19th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO.

What is Finch Therapeutics Group's stock symbol?

Finch Therapeutics Group trades on the NASDAQ under the ticker symbol "FNCH."

How do I buy shares of Finch Therapeutics Group?

Shares of FNCH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Finch Therapeutics Group's stock price today?

One share of FNCH stock can currently be purchased for approximately $8.56.

How much money does Finch Therapeutics Group make?

Finch Therapeutics Group has a market capitalization of $406.42 million.

How many employees does Finch Therapeutics Group have?

Finch Therapeutics Group employs 131 workers across the globe.

What is Finch Therapeutics Group's official website?

The official website for Finch Therapeutics Group is www.finchtherapeutics.com.

How can I contact Finch Therapeutics Group?

The company can be reached via phone at 617-229-6499 or via email at [email protected].


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.